Percutaneous Coronary Intervention Will Retain Decision Resources' Clinical Gold Standard for Stable Angina, According to a New Report from Decision Resources
WALTHAM, Mass., April 20 /PRNewswire/ -- Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that surveyed cardiologists identify a therapy's effect on mortality as the attribute that most influences their prescribing decisions in coronary heart disease (stable angina). Clinical data and the opinions of interviewed thought leaders indicate that current and emerging therapies have no advantage in this attribute over carvedilol (GlaxoSmithKline's Coreg, generics), the sales-leading agent in the market.
The new report entitled Coronary Heart Disease (Stable Angina): To Gain Share, Emerging Therapies Must Not Only Control Symptoms but Also Reduce Mortality also finds that a therapy that reduces plaque volume more than Pfizer's Lipitor/Sortis/Tahor at 18 months would earn a 28 percent patient share in stable angina in the United States and a 37 percent patient share in Europe, according to surveyed U.S. and European cardiologists.
In 2008, Decision Resources' proprietary clinical gold standard for stable angina was percutaneous coronary intervention (PCI). Based on available data and expert opinion, PCI will retain gold-standard status for stable angina in 2012 as surveyed physicians believe it to be the most efficacious therapy for treating the symptoms of stable angina.
"Interestingly, surveyed physicians also indicate that Cardium Therapeutics' gene therapy Generx has great potential in treating stable angina," said Decision Resources Analyst Kate Sullivan, B.S. "However, experts we interviewed believe gene therapy is still at least 10 years away from becoming a viable therapeutic approach for the indication, which leaves PCI, over the next decade, as the most efficacious therapy for providing symptom relief to patients."
About the Report
Coronary Heart Disease (Stable Angina): To Gain Share, Emerging Therapies Must Not Only Control Symptoms but Also Reduce Mortality is a DecisionBase 2009 report. DecisionBase 2009 is a decision-support tool that provides in-depth analysis of unmet need, physician expectations of new therapies and commercial dynamics to help pharmaceutical companies optimize their investments in drug development.
The report can be purchased by contacting Decision Resources. Members of the media may request an interview with an analyst.
About Decision Resources
Decision Resources (www.decisionresources.com) is a world leader in market research publications, advisory services and consulting designed to help clients shape strategy, allocate resources and master their chosen markets. Decision Resources is a Decision Resources, Inc. company.
About Decision Resources, Inc.
Decision Resources, Inc. is a cohesive portfolio of companies that offers best-in-class, high-value information and insights on important sectors of the healthcare industry. Clients rely on this analysis and data to make informed decisions. Please visit Decision Resources, Inc. at www.DecisionResourcesInc.com.
All company, brand, or product names contained in this document may be trademarks or registered trademarks of their respective holders.
For more information, contact: Decision Resources Decision Resources, Inc. Christopher Comfort Elizabeth Marshall 781-296-2597 781-296-2563 email@example.com firstname.lastname@example.org
|SOURCE Decision Resources|
Copyright©2009 PR Newswire.
All rights reserved